Moderna (MRNA) Non-Current Assets (2017 - 2026)

Moderna (MRNA) has 10 years of Non-Current Assets data on file, last reported at $5.7 billion in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $5.7 billion, down 3.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $22.9 billion (down 5.17% YoY), and the FY2025 annual result was $5.8 billion, down 4.12% from the prior year.
• Non-Current Assets slipped to $5.7 billion in Q1 2026 per MRNA's latest filing, from $5.8 billion in the prior quarter.
• Over five years, Non-Current Assets peaked at $12.5 billion in Q2 2022 and troughed at $5.5 billion in Q3 2025.
• A 5-year average of $8.4 billion and a median of $7.1 billion in 2024 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2022 and 2024: Non-Current Assets soared 1036.13% in 2022, then sank 46.66% in 2024.
• A 5-year view of Non-Current Assets shows it stood at $12.4 billion in 2022, then plunged by 34.81% to $8.1 billion in 2023, then dropped by 25.4% to $6.0 billion in 2024, then fell by 4.12% to $5.8 billion in 2025, then retreated by 1.31% to $5.7 billion in 2026.
• Business Quant data shows MRNA's Non-Current Assets at $5.7 billion in Q1 2026, $5.8 billion in Q4 2025, and $5.5 billion in Q3 2025.